4‐Octyl itaconate inhibits inflammation via the NLRP3 pathway in neuromyelitis optica spectrum disorders

Documenti analoghi

• Impact of neuromyelitis optica spectrum disorder on employment and income in the United States
  di: Isabella Gomez Hjerthen, et al.
  Pubblicazione: (2024)
• Characterizing mortality in patients with AQP4‐Ab + neuromyelitis optica spectrum disorder
  di: Anna Francis, et al.
  Pubblicazione: (2024)
• B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
  di: Jeffrey L. Bennett, et al.
  Pubblicazione: (2024)
• Identification of potential biomarkers for neuromyelitis optica by quantitative proteomics
  di: Yaowei Ding, et al.
  Pubblicazione: (2024)
• Effects of intravenous pulse methylprednisolone in neuromyelitis optica during the acute phase
  di: Shengnan Wang, et al.
  Pubblicazione: (2024)